2026’s real breakthrough is translation, not invention

The defining science story of 2026 is not a single invention but a shift in where value is being created: in late-stage proof, regulated workflows, and measurable outcomes. The sharpest example is oncology, where daraxonrasib’s Phase 3 survival signal could reset expectations for pancreatic cancer and the broader RAS field.